Camizestrant

2026年5月27日，阿斯利康官宣，美国食品药品监督管理局（FDA）再度延长其核心管线药物——口服选择性雌激素受体降解剂（SERD）camizestrant的新药上市申请（NDA）审评周期，用于核查企业补充的专项分析数据。 此次审批延期距离FDA肿瘤药物咨询委员会（ODAC）以6:3的投票结果否决该药上市不足一月，让这款备受期待的乳腺癌重磅药物在美国的商业化进程遭遇重大波折。 争议核心：创新试验设计引发监管性质疑 本次camizestrant的上市申请，核心支撑依据为关键III期SERENA-6临床试验结果。该试验采用行业创新的“转换治疗”方案：入组患者先接受芳香化酶抑制剂联合CDK4/6抑制剂的标准一线治疗，在未出现影像学疾病进展、但通过循环肿瘤DNA（ctDNA）检测出ESR1突变后，随机分为两组，一组维持原有治疗方案，另一组将芳香化酶抑制剂替换为camizestrant开展联合治疗。 试验核心数据表现亮眼：患者提前换药治疗后，疾病进展或死亡风险大幅降低56%（HR=0.44，95% CI 0.31-0.60；p<0.00001），中位无进展生存期（PFS）由对照组9.2个月延长至16.0个月。凭借优异的临床获益数据，FDA已于2025年5月授予该创新疗法突破性疗法认定。 但这款创新疗法的试验设计，也成为ODAC专家争议的焦点。在4月30日的专项评审会议中，6名投出反对票的专家一致认为，现有临床数据无法证实，影像学进展前的提前换药方案，能为患者带来实质性、有临床价值的长期获益。核心短板在于目前总生存期（OS）数据尚未成熟，且试验未纳入患者生活质量评估维度，无法佐证该治疗模式可切实改善患者远期预后。 与此同时，FDA对试验的次要终点有效性提出关键质疑。监管机构认为，在该转换治疗试验体系下，第二次疾病进展时间（PFS2）不具备可靠的疗效参考价值。即便阿斯利康披露数据显示，camizestrant组中位PFS2达25.7个月，显著优于对照组的19.1个月，仍未能扭转多数专家的否定态度。企业紧急补救：递交ctDNA补充数据，ASCO将释核心证据 面对ODAC的不利投票结果，阿斯利康快速启动补救措施，向FDA提交多项补充分析数据，其中ctDNA清除率与患者长期疗效的关联性分析是核心佐证材料，旨在进一步夯实camizestrant的临床获益价值。企业官宣，全套详细分析结果将于2026年6月2日芝加哥举办的美国临床肿瘤学会（ASCO）年会正式公开。 阿斯利康肿瘤研发负责人Susan Galbraith公开表态：“我们充分认可SERENA-6试验的核心成果，且委员会已确认camizestrant具备良好的安全性与药物有效性。我们将持续与FDA深度沟通，力争早日将这款创新疗法落地美国、惠及患者。” 目前FDA尚未公布本次延期审评后的最新PDUFA决议日期。结合行业惯例，此类补充数据核查引发的审评延期，周期通常约3个月。值得注意的是，FDA评审结果虽不受咨询委员会意见强制约束，但行业历史数据显示，二者最终结论一致性高达80%，该药后续审批结果仍存在较大不确定性。海内外审批冰火两重天：欧洲率先获批积极意见，敲定商品名 与美国审批遇阻形成鲜明反差的是，camizestrant在欧洲市场顺利推进。2026年5月26日，即FDA官宣延期前一日，欧洲药品管理局（EMA）人用药品委员会（CHMP）已发布积极审评意见，推荐批准camizestrant联合CDK4/6抑制剂用于相同乳腺癌适应症。 欧盟此次审批依据的是与美国申报完全一致的SERENA-6试验数据，直观体现出欧美两大药监体系对创新临床试验模式的评估标准差异。若顺利获得欧盟委员会最终获批，camizestrant将以商品名Etcamah正式登陆欧洲市场。行业常态：FDA审评延期频发，多家跨国药企深陷其中 此次camizestrant审批延期并非个例。受预算缩减、人员编制收紧影响，近年FDA审评效率持续下滑，新药申请延期核查已成为行业普遍现象。 据行业统计，2026年以来，拜耳Lynkuet、Biohaven troriluzole、赛诺菲tolebrutinib等多款创新药物，以及Biogen、Savara、Travere Therapeutics等企业的在研管线，均因FDA补充数据核查需求被延长审评周期。FDA也曾公开坦言，繁重的审评工作量与有限的人力资源，是审批延期的核心原因。管线前景研判：50亿峰值潜力仍存，后续临床成关键 尽管美国上市进程遇挫，行业对camizestrant的长期商业价值仍保持乐观。阿斯利康预判，该药物未来全球峰值销售额有望突破50亿美元，将成为企业肿瘤管线的核心重磅品种。 投行机构古根海姆证券分析指出，即便本次基于SERENA-6试验的适应症申请最终未获FDA批准，也不会对camizestrant整体商业价值造成致命冲击。该试验对应的适应症市场空间相对有限，阿斯利康对这款药物的核心布局重心，在于更广阔的乳腺癌全治疗领域。 目前，阿斯利康仍在稳步推进camizestrant多项后期临床试验，覆盖辅助治疗、一线治疗等核心场景。值得关注的是，其核心竞品罗氏的口服SERD药物，已于2026年3月宣告一线乳腺癌临床试验失败，这让camizestrant成为全球SERD赛道中最具商业化潜力的候选药物之一。 截至目前，阿斯利康尚未披露camizestrant在美国市场的后续审批规划及时间节点。业内将重点关注本次ASCO年会公布的ctDNA核心数据，以及后续大规模临床试验进展，这将直接决定这款50亿级重磅药的最终上市命运。 参考来源：https://www.fiercebiotech.com/biotech/fda-delays-ruling-astrazenecas-breast-cancer-drug-after-negative-adcomm-vote

AstraZeneca submitted an analysis that it will share next week at the ASCO Annual Meeting. \n The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.AstraZeneca filed for FDA approval of the oral SERD based on a phase 3 switching study. Patients in the Serena-6 trial received an aromatase inhibitor and a CDK4/6 inhibitor. After detecting an ESR1 mutation, investigators swapped the aromatase inhibitor for camizestrant. AstraZeneca linked switching to its oral SERD to a 56% jump in progression-free survival.However, the FDA raised questions about the study design, and its advisory committee voted six to three that AstraZeneca failed to show camizestrant provides a clinically meaningful benefit. The vote was a blow to AstraZeneca’s hopes of winning approval, although the FDA can go against advisory committees.After the setback, AstraZeneca provided additional analyses requested by the FDA. The analyses include data on circulating tumor DNA clearance linked to longer-term efficacy outcomes, which AstraZeneca will share next week at the American Society of Clinical Oncology annual meeting. The FDA has pushed back its ruling on whether to approve camizestrant while it reviews the analyses.  AstraZeneca didn’t provide a new decision date. Three-month delays are typical and, during the second Trump administration, have been a common occurrence. After budget cuts shrank its workforce, the FDA delayed rulings on assets including Bayer’s Lynkuet, Biohaven’s troriluzole and Sanofi\'s tolebrutinib. The FDA reportedly blamed a “heavy workload and limited resources” for one delay.The agency has continued to delay rulings this year, with Biogen, Savara and Travere Therapeutics among the companies to reveal the FDA has extended reviews of their molecules. Like AstraZeneca, those three companies suffered delays after submitting additional information that the agency needed time to review.If AstraZeneca’s analyses allay the FDA’s concerns, the Big Pharma could win approval for an asset that it has tipped (PDF) to generate peak sales of more than $5 billion. The forecast could survive the failure to win approval based on the switching study, with Guggenheim Securities analysts describing the Serena-6 study as “a limited commercial opportunity in our and [AstraZeneca’s] view” in a note to investors this month. AstraZeneca is running two adjuvant studies and a trial in a first-line setting as it seeks to establish its drug candidate in multiple parts of the breast cancer care pathway. Roche reported the failure of its rival oral SERD in first-line breast cancer in March, but AstraZeneca executives have argued their trial designs and drug candidate are differentiated.Last week, Europe’s Committee for Medicinal Products for Human Use blessed camizestrant with a positive opinion. The drug will be marketed as Etcamah in Europe.